Concepedia

A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies

Paul K. Paik, Charles M. Rudin, Andrew Brown, Naiyer A. Rizvi, Naoko Takebe, William D. Travis, Leonard P. James, Michelle S. Ginsberg, Rosalyn A. Juergens, Leslie B. Tyson,

Cancer Chemotherapy and Pharmacology · 2010 · 72 citations · 22 references

DOIFull text

Open access

Concepts

References

22

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

Christin Tse, Alexander R. Shoemaker, Jessica Adickes et al. · Cancer Research · 2008 · 2K citations · Full text

, , +16

Programmed Anuclear Cell Death Delimits Platelet Life Span

Kylie D. Mason, Marina R. Carpinelli, Jamie I. Fletcher et al. · Cell · 2007 · 1K citations · Full text

, , +9

Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis

Mai Nguyen, Richard Marcellus, Anne Roulston et al. · Proceedings of the National Academy of Sciences · 2007 · 652 citations · Full text

, , +17

Bcl-2 family proteins are essential for platelet survival

H Zhang, Paul Nimmer, Stephen K Tahir et al. · Cell Death and Differentiation · 2007 · 426 citations

, , +14

Phase I study of obatoclax mesylate (GX15-070), a small molecule pan–Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia

Susan O’Brien, David F. Claxton, Michael Crump et al. · Blood · 2008 · 271 citations · Full text

, , +11